MedaSorb’s commercialization plan calls for CytoSorb to first enter the market in Europe and then in the US, followed by its pipeline of additional products. MedaSorb is initiating a multi-center trial that will enroll up to 80 patients in Germany as a part of their application for the European CE Mark. The CE Mark will allow MedaSorb to market CytoSorb in the EU. The clinical study will utilize CytoSorb as an adjunctive therapy in patients with acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) in the setting of sepsis.
Al Kraus, CEO of MedaSorb, said: “We are pleased to complete the assignment of these important patents to our intellectual property portfolio. This technology expansion further strengthens MedaSorb’s intellectual property portfolio, and increases our total patent portfolio of issued patents to 24.”